Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435112 | 1.00 | AHR (0.50) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL1685392 | 0.87 | AHR (0.50) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL19342487 | 0.84 | AHR (0.38) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL5692312 | 0.83 | AHR (0.56) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL26462532 | 0.83 | AHR (0.47) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL28864005 | 0.82 | AHR (0.53) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL12045263 | 0.80 | KDM4E (0.46) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL7379568 | 0.80 | AHR (0.45) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL14694209 | 0.80 | AOC3 (0.56) | AHRAOC3BRD4RAB9ANPC1 | |
| SCHEMBL7022968 | 0.80 | AHR (0.51) | AHRAOC3BRD4RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239981-A | Phosphonite ligand, catalyst and application thereof in hydroformylation reaction | 万华化学集团股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-113045724-B | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113045724-A | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| WO-2026103793-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| CN-118354623-A | Light emitting device, light emitting apparatus, electronic device, and lighting apparatus | 株式会社半导体能源研究所 | 2024-07-16 | — | — | CN | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-7160933-B2 | Image quality and durability; scratch and smudge resistance; water, humectant and particles comprised of water insoluble dye and polymer phase associated with costabilizer | EASTMAN KODAK COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1460113-B1 | Stable ink jet ink composition and printing method | EASTMAN KODAK CO (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20040186198-A1 | Stable ink jet ink composition and printing method | EASTMAN KODAK COMPANY | 2004-09-23 | — | — | US | disclosed |
| EP-1460113-A1 | Stable ink jet ink composition and printing method | EASTMAN KODAK COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6433112-B1 | COORDINATION POLYMERIZATION CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| US-6239062-B1 | ORGANOMETALLIC COMPOUND OF A GROUP 3 TO 10 TRANSITION OR LANTHANIDE METAL AND A MULTIDENTATE LIGAND CHARACTERIZED BY AN INDOLYL GROUP LINKED TO AN AMIDO GROUP, WHERE THE INDOLYL IS PI-BONDED AND THE AMIDO GROUP IS SIGMA BONDED TO THE METAL | EQUISTAR CHEMICALS, L.P. | 2001-05-29 | — | — | US | disclosed |
| US-3987059-A | ALKYL LITHIUM, CYCLIZATION, DEMETALLIZATION | SANDOZ, INC. (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | AHR 2740/4885AOC3 351/4885BRD4 3044/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | AHR 409/4885AOC3 1555/4885BRD4 1190/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | AHR 1841/4885AOC3 3724/4885BRD4 2321/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | AHR 2681/4885AOC3 1930/4885BRD4 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.